INSIGHT
ADapting for Success in Alzheimer’s: An Ecosystem-Wide Strategy for Market Leadership
Related
Future-Proofing Alzheimer’s Care: Unlocking Innovation to Transform the Alzheimer’s Journey
Shift Health-Led Study Finds That Reported Costs of Alzheimer’s Disease Are the “Tip of the Iceberg”
Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease
The era of clinical failure in Alzheimer’s disease (AD) has decisively ended. Recent regulatory approvals have not only validated disease-modifying approaches but have also unlocked a therapeutic market of historic proportions.
However, with over 140 unique therapies now in the clinical pipeline, the strategic challenge has evolved. Clinical success is now the price of entry, not the key to victory. To achieve market leadership, organizations must look "beyond the molecule" to solve for systemic readiness and prove superior real-world value.
At Shift Health, we recognize that navigating this new reality requires a fundamental transition from a product-centric view to an ecosystem-wide strategy.
The ADapt Framework
Our latest thought piece introduces the ADapt Framework, a strategic structure designed to help leadership teams navigate the complexities of the new AD landscape across four critical pillars:
- Engineer Clinical Differentiation: Moving beyond amyloid-targeting to solve for the ARIA challenge, utilize downstream biomarkers, and prioritize patient-centric endpoints like Activities of Daily Living (ADLs).
- Design for Real-World Success: Prioritizing logistical simplicity—such as subcutaneous administration—and quantifying the impact on the global “hidden” burden of unpaid caregiving.
- Secure Access Through Value: Shifting from defensive to proactive value strategies by engaging HTA bodies early and generating real-world evidence (RWE) that reflects long-term, system-wide savings.
- Shape the Healthcare Ecosystem: Acting as a catalyst to resolve diagnostic bottlenecks through public-private partnerships and co-creating multidisciplinary delivery models.
As the Alzheimer’s market matures, the ultimate winners will be the organizations that execute a holistic strategy to ensure their therapy reaches every patient who needs it.